Hemogenyx receives £600,000 institutional boost
Portfolio Pulse from
Hemogenyx Pharmaceuticals has secured £600,000 in funding from an institutional investor to support phase I clinical trials of its HEMO-CAR-T therapy.
November 11, 2024 | 8:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hemogenyx Pharmaceuticals received £600,000 from an institutional investor to fund phase I trials of its HEMO-CAR-T therapy.
The funding is a positive development as it supports the advancement of Hemogenyx's HEMO-CAR-T therapy into clinical trials, which is a critical step in drug development. This could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80